A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

A Phase 1B, Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Efficacy And Safety Of 4-Week Administration Of Multiple Oral Doses Of PF-04620110 In Type 2 Diabetes Mellitus Subjects With Insufficient Glycemic Control On Metformin

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.

Inclusion Criteria:

• Male and/or female subjects between the ages of 18 and 60 years;
• Body Mass Index (BMI) of >25.0 kg/m2 and <40 kg/m2;
• Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines;
• Subjects who have been on well-tolerated and stable doses of metformin

Exclusion Criteria:

• Recent evidence (6 months prior to screening) or history of unstable major organ disease;
• Diagnosis of Type 1 diabetes mellitus;
• Current medical history of myocardial infarction, unstable angina, or history of stroke (including TIA) within 6 months prior to Screening;
• Treatment with thiazolidinediones (TZDs), or subcutaneously administered antidiabetic agents;